SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001140361-20-009379
Filing Date
2020-04-21
Accepted
2020-04-21 17:07:04
Documents
5
Period of Report
2020-06-05
Effectiveness Date
2020-04-21

Document Format Files

Seq Description Document Type Size
1 DEF 14A nc10007625x1_def14a.htm DEF 14A 755664
2 logo_axsome.jpg GRAPHIC 40418
3 nc10007625x1_linechart01.jpg GRAPHIC 243945
4 nc10007625x1_pc01.jpg GRAPHIC 447230
5 nc10007625x1_pc02.jpg GRAPHIC 375183
  Complete submission text file 0001140361-20-009379.txt   2280068
Mailing Address 200 BROADWAY, 3RD FLOOR NEW YORK NY 10038
Business Address 200 BROADWAY, 3RD FLOOR NEW YORK NY 10038 (212) 332-3241
Axsome Therapeutics, Inc. (Filer) CIK: 0001579428 (see all company filings)

IRS No.: 454241907 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-37635 | Film No.: 20805888
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences